78results about How to "Reduce the frequency of medication" patented technology

The invention discloses a synergistic treatment type multi-material sustained-release eye drop and a preparation method. The preparation method comprises the following steps of: instantaneously forming chitosan aqueous solution which is blended with therapeutic materials into superfine gel particles under the action of direct current high voltage static; receiving the particles by using hyaluronic acid hydrosol or hyaluronic acid hydrogel; and coating the surface of chitosan particles with a hyaluronic acid gel crust layer to obtain a medicament sustained-release eye drop, wherein the size of the chitosan gel particles can be accurately controlled by controlling voltage, the concentration of the chitosan solution and the distance from a jet orifice to the liquid level of the hyaluronic acid hydrosol, and the flowability of the eye drop can be regulated by controlling the concentration of the hyaluronic acid, so that the adhesive capacity of the eye drop to the eye surface and a long-term treatment effect are improved. The preparation method has simple and practicable process, high repeatability, and clean and pollution-free whole preparation process flow; and as the provided multi-therapeutic material sustained-release eye drop for synergistic treatment on eye diseases does not need complicated process, and the proportion of each component and the release rate are convenient to control, so the preparation method has a good application prospect.

The invention provides a compound contraceptive composition, a contraceptive transdermal patch containing the composition and a preparation method. The compound contraceptive composition comprises effective contraceptive quantity of active components dispersed in a skeleton polymer substrate: etonogestrel and estrogen with a contraceptive cooperative function. Drugs are carried out bidirectional regulation by distribution and dispersal in two phases of the skeleton polymer substrate and a pressure sensitive adhesive substrate for drug transdermal release; and a crystallization inhibiting agent is added to a drug warehouse or the pressure sensitive adhesive substrate in order to effectively inhibit the drugs from crystallizing and maintain the long-time continuous transdermal high activity and power of the drugs in the substrates. The contraceptive transdermal patch prepared from the compound contraceptive composition maintains longer (1 to 7 days) stable drug release and blood drug concentration, has better effect, reduces administration frequency, adds user compliance and has obvious advantages in medical application.

The invention discloses a transdermal patch containing pramipexole. The transdermal patch comprises a medicine carrying pressure-sensitive adhesive layer, the pramipexole, solvent and penetration enhancer, wherein the medicine carrying pressure-sensitive adhesive layer comprises acrylate pressure-sensitive adhesive containing carboxyl base groups and acrylate pressure-sensitive adhesive containing hydroxyl base groups, which form mixed pressure-sensitive adhesive; the pramipexole is dissolved in the acrylate mixed pressure-sensitive adhesive, with the content being 10 to 30 weight percent; the content of the mixed pressure-sensitive adhesive is 50 to 80 weight percent; the content of the solvent is 5 to 20 weight percent; the content of the penetration enhancer is 2 to 15 weight percent. The pramipexole can be dissolved in a mixed pressure-sensitive adhesive patch in a high concentration way and is not crystallized, the medicine availability is high, the pramipexole has good stability in pressure-sensitive adhesive matrix, and can be continuously administrated for 5 to 7 days in a transdermal way at a relatively stable permeation rate of being larger than 5.0 micrograms / cm2 / h, and the application area of a pramipexole patch is smaller than 40cm2.

The invention relates to a lipofectin nanometer silver gel and a preparation method of the lipofectin nanometer silver gel. The lipofectin nanometer silver gel is prepared from the following raw materials in parts by weight: 1.5 to 4.5 parts of soya bean lecithin and cholesterol, 1 to 9 parts of chitosan, 1 to 20 parts of glycerol, 0.1 to 2 parts of oleum menthae, 30 to 70 parts of acetum, 20 to 60 parts of nanometer silver solution, and the balance of deionized water. According to the preparation method, the nanometer silver is prepared into lipofectin, most of the nanometer silvers are encapsulated in a bilayer formed by the lipofectin, and therefore the stability of the nanometer silver can be improved; and the proper macromolecular optimum formula is adopted to prepare the gel, thus the convenience is provided for paving medicine on the skin. The prepared preparation has the advantages of being stable in medicine release rate, convenience in medicine paving, low in frequency of using the medicine, free from toxicity and stimulation and high in compliance of a user, and can be used for preventing and treating skin intolerance caused by various pathogenic microorganisms.

The invention discloses fusion proteins and a preparation method thereof, and application of the fusion proteins to medicines used for treating ophthalmic diseases and resisting inflammations and tumors, belonging to the technical field of biopharmaceuticals. According to the invention, a flexible (F) or rigid (R) linker is used for fusing two polypeptides so as to obtain two bifunctional fusion proteins, respectively; that is, the two angiogenesis-inhibiting polypeptides HM-3 and IL-4 are linked with the Fc fragment of an immunoglobulin in virtue of the amino acid linker so as to form multi-functional fusion protein macromolecules. The fusion proteins can improve drug efficacy, prolong half-life and enhance stability, have the characteristics of strong action, low toxicity and the like, and is applicable to the prevention and treatment of solid tumors, various inflammations and neovascular ophthalmic diseases. The fusion proteins are expressed in eukaryotic cells by using a genetic engineering method and are obtained through affinity chromatographic purification.

Disclosed are a dulaglutide injection and the preparation method thereof, the injection containing: dulaglutide, a pH regulator, a solubilizer, an antimicrobial agent, an osmotic pressure regulator, and water for injection, wherein, in addition to water for injection, the content of each component by weight ratio is: dulaglutide:the pH regulator:the solubilizer:the antimicrobial agent: the osmotic pressure regulator 1.5:(2.0-35):(2-5): 7-16:(180-420), and the ratio of the total weight of these five components and the volume of the water for injection in mg / ml is 0.6-1.6.

The invention relates to the technical field of biology, and discloses a whole human TNF alpha (tumor necrosis factor alpha) monoclonal antibody and preparation and application thereof. The invention adopts a whole human antibody technology and acquires an anti-human TNF alpha whole human antibody. Preliminary analyses on the physical, chemical and biological activities of the antibody indicate that the antibody has better affinity with TNF, and can effectively neutralize the killing effect of the TNF on L929 cells in vitro. The whole human TNF alpha monoclonal antibody disclosed by the invention minimizes the immunogenicity of a human body. A PEG (polyethylene glycol) surface modification technology is adopted, thus avoiding the defect of short half life of small molecule antibody, and the whole human TNF alpha monoclonal antibody is more suitable for application in vivo while keeping the anti-TNF alpha activity.